부산대학교 도서관

Objective: The aims of this study were to evaluate therapeutic options of diabetic patients in EndoMed Diabetic Clinic Ulaanbaatar Mongolia. Methods: We studied 101 (54 male, 47 female) Type 2 diabetic patients and their antihyperglycemic therapy prescribed by endocrinologists. Therapeutic options evaluated by the position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) - Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach and compaired with currently available glucose-lowering agents in the world such as Biguanides, Sulfonylureas, Meglitinides, Thiazolidinediones, α -Glucosidase inhibitors, Bile acid sequestrants, Dopamine-2 agonists, GLP-1 receptor agonist or DPP-4 inhibitors and Insulins. Results: Diabetic patients mean age was 51.96 ± 11.11 (Range 18-77) years old. Mean weight was 79.2 ± 1.61 (50-124) kg, mean height was 165 ± 8.68 (142-185) cm, and mean BMI was 28.78 ± 5.25 (18.5-41.5) kg/㎡. Diabetic patients with diet and exercise alone was 101 (100%), combination therapy with oral hypoglycemic agents and bed time insulin were 6 (5.9%), hypoglycemic agents therapy were 75 (74.3%) and insulin therapy was 20 (19.8%). Biguanides was 80 (79.2%), DPP-4 inhibitors was 68 (67.3%) and sulfonylureas was 38 (37.6%) in hypoglycemic agents therapy. Combination therapy with biguanides and DPP-4 inhibitors 67 (66.3%) or combination with biguanides DPP-4 inhibitors and sulfonylureas 38 (37.6%) inpatients of diabetic clinic. Conclusion: Most of diabetic patients in Mongolia on combination drug therapy by biguanides and DPP-4 inhibitors. Meglitinides, Thiazolidinediones, α -Glucosidase inhibitors, Bile acid sequestrants, Dopamine-2 agonists and GLP-1 receptor agonist are no prescribed.